Intranasal Ketamine Versus Subcutaneous Ketamine for Treatment of Post-traumatic Acute Pain in the Emergency Department ( INVESCK )
Launched by UNIVERSITY OF MONASTIR · Feb 5, 2022
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
The INVESCK trial is studying two different ways to manage severe pain from limb injuries in patients visiting the emergency department (ED). Researchers want to compare the effectiveness of intranasal ketamine, which is a medication given through the nose, to subcutaneous ketamine, which is injected just under the skin. Both methods aim to provide quick and effective pain relief for patients suffering from acute trauma pain.
To be eligible for this trial, participants should be between 18 and 75 years old and must have experienced recent limb trauma with a pain level of 5 or higher on a scale from 0 to 10. However, certain individuals cannot join, including those who are pregnant, have severe health issues, or have specific medical histories like head injuries or mental health conditions. If you join the trial, you can expect to receive one of the treatments and be monitored by healthcare professionals to see how well it works for your pain. Your safety and comfort will be prioritized throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patients who presented to the ED with acute limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11 point (0-10).
- • Pain was considered traumatic if it is reported as appearing immediately after the trauma and no anterior pain was described in the same limb.
- Exclusion Criteria:
- • Pregnancy/Breastfeeding
- • altered mental status (GCS\<15)
- • Allergy to ketamine or morphine
- • Weight less than 40 kg or greater than 100kg
- • Unstable vital signs (systolic blood pressure \<90 or \> 180mmHg, pulse rate\<50 or \>150bpm, and respiration rate \<10 or \>30 breath/min)
- • Medical history of acute head or eye injury
- • Medical history of seizure
- • Medical history of intracranial hypertension,
- • Medical history of chronic pain,
- • Medical history of severe renal or hepatic insufficiency.
- • Medical history of glaucoma
- • Alcohol or drug abuse
- • Psychiatric illness,
- • Recent (4 hours before) analgesic agent use.
About University Of Monastir
The University of Monastir, a prominent educational and research institution in Tunisia, is dedicated to advancing medical and clinical research through its innovative programs and collaborations. With a strong emphasis on improving healthcare outcomes, the university actively sponsors clinical trials that explore new therapeutic approaches and enhance patient care. Leveraging its state-of-the-art facilities and a diverse team of experienced researchers and clinicians, the University of Monastir aims to contribute significantly to the global body of medical knowledge while fostering a culture of scientific inquiry and excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Monastir, , Tunisia
Patients applied
Trial Officials
Nouira Semir, Professor
Principal Investigator
University of Monastir
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials